Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2021 | $14.00 → $11.00 | Buy | HC Wainwright & Co. |
Lineup includes one Buffered product and four Fixed Income products in AB's ETF suite NASHVILLE, Tenn., Dec. 13, 2023 /PRNewswire/ -- AllianceBernstein Holding L.P. (NYSE:AB) and AllianceBernstein L.P., a leading global investment management and research firm, announced today the launch of five active exchange-traded funds (ETFs) on the NASDAQ and New York Stock Exchange (NYSE) Arca: AB Conservative Buffer ETF (NASDAQ:BUFC), AB Tax-Aware Intermediate Municipal ETF (NYSE:TAFM), AB Tax-Aware Long Municipal ETF (NYSE:TAFL), AB Corporate Bond ETF (NASDAQ:EYEG), and AB Core Plus Bond ETF (NASDAQ:CPLS). "On the heels of crossing the $1 billion threshold in active ETF AUM, these new ETFs will prov
SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company's aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Company's newly revamped clinical development strategy is available in the Investors section of the Company's new website at www.kiorapharma.com. "T
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. ("Bayon") and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a ‘molecular p
10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)
D - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. ("Bayon") and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a ‘molecular p
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately. He brings strategic expertise, scientific acumen and drug development experience in ophthalmology, otology and regenerative medicine t
WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company’s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company. “We are very pleased to welcome these esteemed leaders to our board as we navigate our
HC Wainwright & Co. reiterated coverage of Eyegate Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously
Alliance Global Partners reiterated coverage of EyeGate Pharmaceuticals with a rating of and set a new price target of $16.75 from $15.50 previously
4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
3 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)
4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)